Surveillance after surgery for stage IV colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial uses a blood test (MRD) to monitor for cancer return after surgery in patients with stage IV colorectal cancer that can be removed. The goal is to catch any recurrence early and guide further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage IV colorectal cancer that is adenocarcinoma (a common type) and has not been treated with surgery yet.
- You have not received chemotherapy, radiation, targeted therapy, or other cancer treatment for this cancer.
- Your surgeons believe they can remove all visible cancer (primary tumor and any spread).
- You are in good general health (ECOG 0-1, meaning you can do all your normal activities).
- You are willing to come back to the hospital for regular follow-ups and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches for signs of leftover cancer after surgery using a blood test (MRD). It is for people with early-stage colon cancer who have not yet had any treatment other than surgery.
This trial tests whether a special blood test (MRD) can help monitor your rectal cancer after surgery, to catch any signs of remaining cancer early. It's for people with advanced but not metastatic rectal cancer that can be removed with surgery, and who haven't started any cancer treatment yet.
This trial is for people with stage III colorectal cancer who haven't had treatment yet. It tests a blood test to find tiny bits of cancer DNA (MRD) after surgery, which may help doctors know if more treatment is needed.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.